Related Experiment Videos
Alzheimer disease therapeutics.
1Alzheimer Disease Research Unit, Center for Aging Genetics and Neurodegeneration, Massachusetts General Hospital, Boston, USA.
Journal of Neuropathology and Experimental Neurology
|October 9, 2001
Summary
Alzheimer disease (AD) involves brain changes like amyloid plaques and neuron loss. Current treatments focus on improving cognition by targeting brain chemistry, while new research explores neuroprotection and anti-amyloid strategies.
Area of Science:
- Neuroscience
- Neurology
- Pathology
Background:
- Alzheimer disease (AD) is pathologically defined by cholinergic deficits, amyloid plaques, neurofibrillary tangles, gliosis, and neuronal/synaptic loss.
- Current primary therapies involve cholinesterase inhibitors to augment cholinergic function, offering modest cognitive benefits.
Purpose of the Study:
- To review the pathological hallmarks of Alzheimer disease.
- To explore current and emerging therapeutic strategies targeting AD pathophysiology.
- To discuss neuroprotective approaches and anti-amyloid strategies for AD management.
Main Methods:
- Review of pathological characteristics of Alzheimer disease.
- Analysis of therapeutic approaches based on AD pathology.
- Examination of research on neurodegenerative processes and neuroprotection.
Main Results:
- Cholinergic deficits are a key pathological feature, addressed by cholinesterase inhibitors.
- Research focuses on AD-specific processes (amyloid, tau, ApoE) and general neurodegeneration (inflammation, oxidation, apoptosis).
- Emerging strategies include estrogen, antioxidants, anti-inflammatories, and anti-amyloid therapies.
Conclusions:
- Understanding AD pathology guides therapeutic development.
- Cholinergic augmentation provides symptomatic relief.
- Neuroprotective and anti-amyloid strategies represent promising avenues for disease modification and prevention.